(CercleFinance.com) – Sanofi announces that the CHMP of the European Medicines Agency has issued a favorable opinion concerning Fexinidazole Winthrop as the first oral treatment for the acute form of sleeping sickness, endemic in East Africa and southern.
This favorable opinion concerns the treatment, in adults and children aged six years or over weighing at least 20 kg, of the first and second stages of sleeping sickness caused by Trypanosoma brucei (Tb) rhodesiense.
CHMP opinion paves the way for updating WHO guidelines on the treatment of sleeping sickness, as well as WHO distribution of Fexinidazole Winthrop in African countries where Tb rhodesiense is present .
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
